Thomas Harding - Jul 1, 2021 Form 4 Insider Report for Clovis Oncology, Inc. (CLVS)

Role
Executive Vice President and Chief Scientific Officer
Signature
/s/ Thomas C. Harding
Stock symbol
CLVS
Transactions as of
Jul 1, 2021
Transactions value $
-$151
Form type
4
Date filed
7/6/2021, 04:16 PM
Previous filing
Jun 3, 2021
Next filing
Aug 3, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLVS Common Stock Options Exercise +63 +5.1% 1.3K Jul 1, 2021 By wife F1
transaction CLVS Common Stock Sale -$151 -26 -2% $5.79* 1.27K Jul 1, 2021 By wife F2
holding CLVS Common Stock 1.73K Jul 1, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLVS Restricted Stock Units Options Exercise $0 +63 +50.81% $0.00 187 Jul 1, 2021 Common Stock 63 By wife F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2 Represents the shares automatically sold by the reporting person's wife pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3 On July 1, 2020, the reporting person's wife was granted 250 Restricted Stock Units. 25% of such Restricted Stock Units vested on July 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Remarks:

Executive Vice President and Chief Scientific Officer